W
WAVEMAN · COMPANY
VOR · Vor Biopharma Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

VOR

Vor Biopharma Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001817229
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-$49.4M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
74
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
1
codes C/M, not in net · $5.6K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$49.4M over 180 days
-$4.2K over 90 days · -$49.4M of it by a 10%+ holder
below 94% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
74 funds added or opened last quarter
more than 55% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$49.4M across 3 people in 180 days.
74 funds added or opened positions in the latest 13F quarter, of 104 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -39.3%
-39.3%12M
-83%-49%-15%+19%2025-092025-102025-122026-032026-052026-072026-09 2026-04-06 · Kolchinsky Peter sold $8.9M2026-04-13 · RA CAPITAL MANAGEMENT, L.P. sold $8.6M2026-04-17 · RA CAPITAL MANAGEMENT, L.P. sold $7.5M2025-10-29 · Kolchinsky Peter sold $6.3M2026-04-08 · Shah Rajeev M. sold $5.8M2025-10-17 · Shah Rajeev M. sold $5.1M2026-04-02 · Kolchinsky Peter sold $4.7M2025-10-16 · Shah Rajeev M. sold $3.3M2026-04-20 · RA CAPITAL MANAGEMENT, L.P. sold $2.7M2026-04-22 · Shah Rajeev M. sold $2.6M2025-10-27 · RA CAPITAL MANAGEMENT, L.P. sold $2.6M2026-04-14 · RA CAPITAL MANAGEMENT, L.P. sold $2.5M2025-10-28 · Kolchinsky Peter sold $2.4M2026-04-09 · Shah Rajeev M. sold $2.2M2026-04-08 · Shah Rajeev M. sold $2.2M2025-10-23 · RA CAPITAL MANAGEMENT, L.P. sold $2.2M2025-10-20 · RA Capital Nexus Fund, L.P. sold $2.1M2025-10-08 · Reprogrammed Interchange LLC sold $2.1M2025-10-15 · Reprogrammed Interchange LLC sold $1.6M2025-10-24 · RA CAPITAL MANAGEMENT, L.P. sold $1.5M2025-10-15 · Shah Rajeev M. sold $1.3M2025-10-06 · Reprogrammed Interchange LLC sold $1.3M2025-10-10 · Reprogrammed Interchange LLC sold $1.3M2025-09-03 · Hoffman Reid sold $1.1M2025-10-09 · Reprogrammed Interchange LLC sold $1.1M2025-10-28 · Kolchinsky Peter sold $1.0M2025-10-14 · Reprogrammed Interchange LLC sold $1.0M2025-10-17 · Shah Rajeev M. sold $998.4K2025-10-07 · Reprogrammed Interchange LLC sold $934.8K2025-10-17 · Shah Rajeev M. sold $931.4K2025-09-08 · Hoffman Reid sold $924.2K2025-09-09 · Hoffman Reid sold $898.5K2025-09-04 · Hoffman Reid sold $874.3K2026-04-15 · RA CAPITAL MANAGEMENT, L.P. sold $858.8K2025-09-05 · Hoffman Reid sold $788.0K2026-04-06 · Kolchinsky Peter sold $774.2K2025-10-17 · Reprogrammed Interchange LLC sold $746.1K2025-10-21 · RA Capital Nexus Fund, L.P. sold $703.5K2025-09-16 · Hoffman Reid sold $688.8K2025-10-06 · Reprogrammed Interchange LLC sold $685.8K2025-09-15 · Hoffman Reid sold $656.0K2025-10-06 · Reprogrammed Interchange LLC sold $639.4K
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $49.4M sold by insiders over 180 days, 74 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Vor Biopharma Inc. insiders sold a net $49.4M of stock across 95 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
RA CAPITAL MANAGEMENT, L.P.
—
SELL
2026-07-16
213.0
$4.2K
Shah Rajeev M.
Director
SELL
2026-04-22
165,150.0
$2.6M
RA CAPITAL MANAGEMENT, L.P.
Director
SELL
2026-04-20
171,963.0
$2.7M
RA CAPITAL MANAGEMENT, L.P.
Director
SELL
2026-04-17
458,411.0
$7.5M
RA CAPITAL MANAGEMENT, L.P.
Director
SELL
2026-04-15
53,644.0
$858.8K
95 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 90 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
TCG Crossover Management, LLC
5,673,078.0 sh
$104.4M
FMR LLC
4,932,149.0 sh
$90.8M
FCPM III SERVICES B.V.
4,117,354.0 sh
$75.8M
BlackRock, Inc.
3,468,107.0 sh
$63.8M
Venrock Adviser, LLC
3,041,719.0 sh
$56.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Simplify Propel Opportunities ETF
$954.6K POSITION · AS OF 2026-03-31
1.4%
Select Biotechnology Portfolio
$23.7M POSITION · AS OF 2026-02-28
0.4%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$16.6M POSITION · AS OF 2026-03-31
0.2%
PROFUND VP BIOTECHNOLOGY
$92.6K POSITION · AS OF 2026-03-31
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
$779.0K POSITION · AS OF 2026-04-30
0.2%
BIOTECHNOLOGY ULTRASECTOR PROFUND
$241.1K POSITION · AS OF 2026-04-30
0.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 7 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
4
Phase 3
2 ACTIVE
1
Not applicable
0 ACTIVE
2
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-371.6M$-121.2M$-126.0M$-93.4M
NET INCOME$-696.0M$-116.9M$-117.9M$-92.1M
EPS (DILUTED)-70.50-34.03-1.75-2.33
OPERATING CASH FLOW$-142.7M$-99.7M$-100.3M$-85.1M
CASH$396.5M$81.9M$31.4M$57.7M
DIVIDENDS PAID$0$0$0$0
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →